|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1997-2-6
|
|
pubmed:abstractText |
Epidermal growth factor receptor (EGFR) is an operationally specific antigen in malignant gliomas; it is overexpressed in > 60% of these tumors, whereas its expression is very low in normal brain. This study aimed to evaluate whether an adequate amount of an anti-EGFR monoclonal antibody (MAb) could reach a tumor after a single intravenous administration.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0148-396X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
39
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
478-83
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:8875477-Adult,
pubmed-meshheading:8875477-Aged,
pubmed-meshheading:8875477-Animals,
pubmed-meshheading:8875477-Antibodies, Monoclonal,
pubmed-meshheading:8875477-Antibody Specificity,
pubmed-meshheading:8875477-Brain Neoplasms,
pubmed-meshheading:8875477-Combined Modality Therapy,
pubmed-meshheading:8875477-Dose-Response Relationship, Drug,
pubmed-meshheading:8875477-Female,
pubmed-meshheading:8875477-Glioma,
pubmed-meshheading:8875477-Humans,
pubmed-meshheading:8875477-Infusions, Intravenous,
pubmed-meshheading:8875477-Male,
pubmed-meshheading:8875477-Metabolic Clearance Rate,
pubmed-meshheading:8875477-Mice,
pubmed-meshheading:8875477-Middle Aged,
pubmed-meshheading:8875477-Premedication,
pubmed-meshheading:8875477-Receptor, Epidermal Growth Factor
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas.
|
|
pubmed:affiliation |
Department of Neurosurgery, Hôpital de la Pitié, Paris, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
